Subcutaneous Implantable Cardioverter-Defibrillator Finding a Place in Sudden Cardiac Death Prevention
نویسندگان
چکیده
منابع مشابه
Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience.
BACKGROUND Recently, subcutaneous implantable cardioverter-defibrillator (S-ICD) has become available. The aim of our study was to assess the efficacy of S-ICD in a clinical setting. METHODS AND RESULTS Between June 2010 and July 2011, 40 consecutive patients (42 ± 15 years; body mass index, 27 ± 6 kg/m(2); left ventricular ejection fraction, 47 ± 15%; 28 men) received an S-ICD for primary (n...
متن کاملSubcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death
Implantation of a transvenous implantable cardioverter-defibrillator (ICD) is a recognized method of secondary prevention of sudden cardiac death [1]. In some patients with indications for such a device, circumstances may occur that render ICD implantation difficult or impossible. Implantation of a subcutaneous ICD (S-ICD), not requiring introduction of any elements into the cardiovascular syst...
متن کاملSubcutaneous implantable cardioverter-defibrillator.
or nearly 3 decades, the implantable cardioverter-defibrillator (ICD) has been available to patients who survived life-threatening rapid heart rhythms or are at risk of experiencing them. The ICD comprises a device generator coupled with a defibrillation lead. Traditional ICDs are implanted under the skin with the generator positioned beneath the collar bone. The defibrilla-tion lead is inserte...
متن کاملOutcomes After Implantable Cardioverter-Defibrillator Generator Replacement for Primary Prevention of Sudden Cardiac Death.
BACKGROUND The effectiveness of implantable cardioverter-defibrillators (ICDs) for primary prevention of sudden death in patients with an ejection fraction (EF) ≤ 35% and clinical heart failure is well established. However, outcomes after replacement of the ICD generator in patients with recovery of EF to >35% and no previous therapies are not well characterized. METHODS AND RESULTS Between 2...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2017
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2017.06.055